Dr. Louis Flamand is a full professor and vice-chair of the department of microbiology-infectious disease-immunology at the Laval University School of Medicine and senior researcher in the division of infectious and immune diseases at the CHU de Quebec Research Center. Before joining Laval University, Dr. Flamand obtained his PhD at the University of Montreal and post-doctoral training that the National Institutes of Health and at the Institute of Human Virology (Maryland, USA). He received his MBA in pharmaceutical management from Laval University. Since 2008, he has been President of the biohazards risk committee at Laval University. He has also been a member of the HHV-6 Foundation scientific advisory board since 2006. Dr. Flamand has experience in pre-clinical development. Throughout his career, Dr. Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology. Dr. Flamand is the author of more than 80 peer-reviewed publications and is lead Editor of the book “Human Herpesviruses HHV-6A, HHV-6B & HHV-7: Diagnosis and Clinical Management” 3rd edition.

Biological consequences of chromosomal integration by human herpesvirus 6 (HHV-6).

HHV-6 has the remarkable ability to integrate its genome in the cells that it infects. Remarkably, about 1% of the population carries a copy of the viral genome integrated in a chromosome of each cell. These individuals, referred to as inherited-chromosomally-integrated individuals (iciHHV-6), represent one of the main topics studied by Dr. Flamand and his team. HHV-6 genome integration occurs near the ends of chromosomes, in the telomere. Telomeres play a major role in cellular homeostasis by protecting the ends of chromosomes against the development of the DNA damage response, and play a key role in the long-term proliferative capacity of cells. It is therefore anticipated that the presence of the integrated virus in the telomere of ici HHV-6+ individuals may represent a risk factor for the development of various diseases. Dr. Flamand and his team recently reported that iciHHV-6+ subjects are 3X more at risk for developing angina pectoris, a cardiovascular disease (Gravel et al 2015 PNAS). Work in progress in the laboratory is aimed at better understanding the link between HHV-6 integration and the development of angina.

Understand the molecular and cellular mechanisms that lead to HHV-6 chromosomal integration.

Dr. Flamand’s laboratory is interested in identifying the mechanisms and viral/cellular factors underlying HHV-6 integration. Having successfully developed a cell culture model allowing them to study the integration of HHV-6, Dr. Flamand and his team are currently studying the viral and cellular proteins that play a role in HHV-6 integration process.

CHUL
2705, boulevard Laurier
T1-64
Québec, Québec
Canada G1V 4G2
113 entries « 1 of 12 »

Willett JDS, Gravel A, Dubuc I, Gudimard L, Dos Santos Pereira Andrade AC, Lacasse É, Fortin P, Liu JL, Cervantes JA, Galvez JH, Djambazian HHV, Zwaig M, Roy AM, Lee S, Chen SH, Ragoussis J, Flamand L

SARS-CoV-2 rapidly evolves lineage-specific phenotypic differences when passaged repeatedly in immune-naïve mice

Journal Article

Commun Biol, 7 (1), 2024.

Abstract | Links:

Gauvin J, Huynh DN, Dubuc I, Lê C, Tugores R, Flamand N, Flamand L, Lubell WD, Ong H, Marleau S

Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator

Journal Article

Front Pharmacol, 15 , 2024.

Abstract | Links:

Collin V, Biquand É, Tremblay V, Lavoie ÉG, Blondeau A, Gravel A, Galloy M, Lashgari A, Dessapt J, Côté J, Flamand L, Fradet-Turcotte A

The immediate-early protein 1 of human herpesvirus 6B interacts with NBS1 and inhibits ATM signaling

Journal Article

EMBO Rep, 25 (2), 2024.

Abstract | Links:

Allaeys I, Lemaire G, Leclercq M, Lacasse E, Fleury M, Dubuc I, Gudimard L, Puhm F, Tilburg J, Stone AP, Machlus KR, Droit A, Flamand L, Boilard E

SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow

Journal Article

Blood Adv, 2024.

Abstract | Links:

Aimola G, Wight DJ, Flamand L, Kaufer BB

Excision of Integrated Human Herpesvirus 6A Genomes Using CRISPR/Cas9 Technology

Journal Article

Microbiol Spectr, 11 (2), 2023.

Abstract | Links:

Lacasse É, Gudimard L, Dubuc I, Gravel A, Allaeys I, Boilard É, Flamand L

SARS-CoV-2 Nsp2 Contributes to Inflammation by Activating NF-κB

Journal Article

Viruses, 15 (2), 2023.

Abstract | Links:

Colmegna I, Valerio V, Amiable N, Useche M, Rampakakis E, Flamand L, Rollet-Labelle E, Bessette L, Fitzcharles MA, Hazel E, McCormack D, Michou L, Panopalis P, Langlois MA, Bernatsky S, Fortin PR

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

Journal Article

RMD Open, 9 (4), 2023.

Abstract | Links:

Puhm F, Allaeys I, Lacasse E, Dubuc I, Galipeau Y, Zaid Y, Khalki L, Belleannée C, Durocher Y, Brisson AR, Wolberg AS, Langlois MA, Flamand L, Boilard E

Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells

Journal Article

Blood Adv, 6 (12), 2022.

Abstract | Links:

Puhm F, Flamand L, Boilard E

Platelet extracellular vesicles in COVID-19: Potential markers and makers

Journal Article

J Leukoc Biol, 111 (1), 2022.

Abstract | Links:

Collin V, Flamand L

[The importance of telomeres in human herpesvirus-6A/B infections]

Journal Article

Med Sci (Paris), 38 (2), 2022.

Abstract | Links:

113 entries « 1 of 12 »
Signaler des ajouts ou des modifications

Active projects

  • Collaboration entre les laboratoires d’Amélie Fradet-Turcotte (AFT) et Louis Flamand (LF) sur l’étude des mécanismes de réponses aux dommages à l’ADN et les infections virales, from 2023-04-24 to 2025-04-23
  • Coronavirus Variants Rapid Response Network: CoVaRR-Net, from 2021-03-01 to 2025-03-31
  • Dissecting the pathological consequences of neurological infections by herpesviruses, using human iPSC-derived cultures, from 2021-04-01 to 2026-03-31
  • Human herpesvirus 6 and chromosomal integration, from 2023-04-01 to 2028-03-31
  • Pathogenesis and immune escape potential of SARS-CoV-2 variants of concern, from 2021-06-01 to 2025-03-31
  • Pathogenic roles of platelets in sepsis, from 2020-03-01 to 2025-03-31

Recently finished projects

  • Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, from 2021-12-01 to 2022-11-30
  • COVID-19 trilogy: ARDS, inflammation and coagulopathy, from 2020-06-01 to 2024-03-31
  • COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, from 2021-03-16 to 2023-03-31
  • Effect of cigarette smoke/e-cigarette vapor and SARS-CoV-2 infection on oral, nasal, and bronchial epithelial cell responses, from 2020-04-01 to 2022-12-31
  • Human herpesvirus 6 and chromosomal integration, from 2018-04-01 to 2023-03-31
  • Role of antibodies in platelet response to SARS-CoV-2 and its variants, from 2021-06-01 to 2022-05-31
  • The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, from 2020-04-01 to 2023-03-31
  • Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28
Data provided by the Université Laval research projects registery